---
title: High-Quality and Cost-Effective Plasmid Platform
description: WuXi Advanced Therapies showcases how to address prominent market challenges to provide high-quality, cost-effective plasmid DNA solution.
---

[![BPI Media_Logo 2_Color 1](https://bpi.bioprocessintl.com/hs-fs/hubfs/BPI%20Media_Logo%202_Color%201.png?width=350&height=161&name=BPI%20Media_Logo%202_Color%201.png)](https://bioprocessintl.com/)

# ![New-ATE-Logo2019](https://bpi.bioprocessintl.com/hs-fs/hubfs/New-ATE-Logo2019.png?width=700&name=New-ATE-Logo2019.png)

## High-Quality and Cost-Effective Plasmid Platform

 Please join us for this free, live Ask the Expert webcast.

Just fill out the form below to register.

|  |
| --- |

## Presenter:

******![Wuxi March 11 Speaker](https://bpi.bioprocessintl.com/hs-fs/hubfs/Wuxi%20March%2011%20Speaker.jpg?width=148&name=Wuxi%20March%2011%20Speaker.jpg)******

**Dr. Shuyuan Yao**

 Chief Scientific Officer and Head of Research & Technology Development

WuXi Advanced Therapies

 

Dr. Shuyuan Yao received his PhD in molecular and medical genetics from The University of Toronto School of Medicine and accomplished postdoctoral research in stem biology at The Scripps Research Institute (TSRI), San Diego, California. From 2006 to 2014, Dr. Yao worked in Sangamo BioScience, StemGent Inc. and Allen Institute for Brain Science, and so on. In 2014, Dr. Yao moved back to China and worked at Vertex Pharmaceuticals R&D (Shanghai) Co., Ltd. Dr. Yao joined WuXi AppTec in November 2014. From 2014 to 2016, Dr. Yao served as Senior Director of Cell Therapy Research and headed the Cell Therapy Research Department. From 2016 to 2018, Dr. Yao served as VP of Operations at JW Therapeutics Co., Ltd., leading the company’s R&D, manufacturing, and operations. Dr. Yao now serves As Chief Scientific Officer and Head of Research & Technology Development of WuXi Advanced Therapies of WuXi ATU Co., Ltd. Dr. Yao has established and managed several start-up projects and companies and has strong experience in R&D, manufacturing, facility, team, and project management.

## About this event:

#### Date: March 11, 2021

#### Time: 11 am EST | 8 am PST | 5 pm CET

#### Duration: 15 minutes

 

In recent years, the demand for cell and gene therapy has increased substantially. The success in gene and cell therapy has also increased demand for plasmid DNA. In supplying the industry with high-quality plasmid DNA, key prominent market challenges are capacity availability, accelerated turnaround time (TAT), and affordability. In this presentation, WuXi Advanced Therapies will showcase how to address these prominent challenges to provide high-quality, cost-effective, and accelerated TAT for good manufacturing practice (GMP) grade and GMP plasmid DNA market supply to help accelerate customer’s pipeline to market.

Key takeaways:

- High-quality and cost-effective plasmid DNA solution
- Flexible facility with accelerated TAT
- Capabilities of ATU plasmid platform
- WuXi ATU GMP plasmids and manufacturing experience

-  

-  

©2015 BioProcess International All Rights reserved